Asset
INTERFERON BETA-1A
Revenue
No revenue reported in loaded filings.
Clinical trials (18)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01416207 | phase1 | completed | 2011-08-01 | 2011-10-01 | Biogen | A Multiple-Dose, Open-Label, Phase 1, Pharmacokinetic, Pharmacodynamic, and Safety Study of Avonex® in Chinese Healthy Volunteer Subjects |
| NCT00771043 | phase4 | withdrawn | 2008-11-01 | 2009-08-01 | Biogen | A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a |
| NCT01119677 | phase1 | completed | 2010-05-05 | 2010-10-23 | Biogen | A Study of Avonex to Determine the Effects of Dose Titration on the Incidence of Flu Like Symptoms in Healthy Volunteers |
| NCT01181115 | phase3 | completed | 2010-04-01 | 2011-10-01 | Biogen | Avonex Safety and Tolerability in Chinese Subjects With Relapsing Multiple Sclerosis (MS) |
| NCT01500408 | phase1 | completed | 2012-01-01 | 2012-04-01 | Biogen | Demonstrate the Bioequivalence of Interferon Beta-1a (INFB) Manufactured by Two Different Processes in Healthy Volunteers |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| BLA 103628 | BLA | Biogen Inc. |
Marketed products (3)
- AVONEX
- Avonex
- Avonex